UK markets closed
NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.40 -0.50 (-0.02%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,013.23 +111.69 (+0.20%)
Supernus Pharmaceuticals, Inc. (0LB2.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 04:44PM BST
| Previous close | 30.17 |
| Open | 28.49 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 28.49 - 28.49 |
| 52-week range | 22.54 - 38.65 |
| Volume | |
| Avg. volume | 83 |
| Market cap | 12.725M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 0.22 |
| EPS (TTM) | 1.31 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Despite Challenges, Company Shows Promising Growth in Key Areas
Simply Wall St.Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals ( NASDAQ:SUPN ) First Quarter 2024 Results Key Financial Results Revenue: US$143.6m (down 6.6...
GlobeNewswireSupernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will
© 2024 Yahoo. All rights reserved.